Aridis Pharmaceuticals Inc 's (NASDAQ:ARDS) monoclonal antibody cocktail treatment is potentially first-in-class, H.C. Wainwright analyst Vernon Bernardino told investors Wednesday.
Last week Aridis announced that the drug, AR-701, is broadly reactive against Omicron and other Covid-19 variants, SARS (Severe Acute Respiratory Syndrome), MERS (Middle East Respiratory Syndrome Coronavirus), and the common cold, which is a type of human coronavirus.
According to TheFly, Bernardino, who reiterated a buy rating and $19 price target on Aridis shares, said the cocktail "binds to the S2 spike protein subunit, which mediates viral cell membrane fusion in SARS-CoV-2 variants and also binds to the omicron variant with no loss in affinity compared to the original Wuhan strain."
The analyst is now looking for the initiation of phase 1 testing as a positive for Aridis Pharmaceuticals' share price next year.
H.C. Wainwright's positive comments on Aridis follow similar comments from Cantor Fitzgerald, which last week said Aridis' pipeline is "underappreciated."
https://finance.yahoo.com/news/h-c-wainwright-bullish-aridis-110524556.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.